Adam Linley, PhD, is a Postdoctoral Research Associate and Leuka John Goldman Research Fellow at the University of Liverpool, Liverpool, UK. Dr Linley obtained his undergraduate bachelor’s in biomedical sciences from the Nottingham Trent University, Nottingham, UK, in 2006, where he stayed to undertake his PhD in tumor biology. After obtaining his undergraduate degree he trained to become a biomedical scientist, qualifying in 2007 at the Nottingham University Hospital, Nottingham, UK. After receiving his PhD, Dr Linley practiced as a Postdoctoral Research Associate at the Nottingham Trent University, Nottingham, UK. He then moved to Southampton to become a Postdoctoral Research Fellow and then a Senior Researcher at the University of Southampton, Southampton, UK, until 2015.
Speaking on CLL, AML, gene editing and kinomics
Dr Linley’s research interest lies in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and novel therapies. He has pivotal publications in gene editing using CRISPR-Cas9 in AML patients, as well as studies investigating the kinome profiles in CLL.